WeedLife News Network

Independent consultancy NNE and venture advisory firm Volvér showcase the significance of science and risk in devising a manufacturing facility.

How can cannabis producers bring a high quality, reliable product onto the market? Morten Allesoe, Principal Consultant and Christian Carlsen, Venture Partner at independent consulting firm NNE, tell MCN about the importance of factoring in scientific evidence and risk awareness.

“We have previously discussed various steps in the journey from having an idea as an investor or entrepreneur, to creating and delivering the product to the patient and the processes that take place within the body once the patient consumes the product – but we are still missing some of the steps between the initial idea and the launch of an operational facility,” explains Business Director Christian Carlsen.

“We advise our customers to take the science- and risk-based approach with a heavy patient focus, but this is a factor that migrates into the broader strategy on how to qualify the facility and the equipment,” says Principal Consultant Morten Allesoe.

How can a focus on science and risk help solve the challenges faced by medical cannabis producers in an emerging market?

Pharmaceutical engineering and consulting company NNE has provided advice and support to an increasing number of medical cannabis clients in recent years. As the nascent medical cannabis industry has grown and developed, both in Europe and elsewhere, Carlsen has identified some key differences between the field of medical cannabis and the traditional pharmaceutical sector.

Cannabis is advertised, sometimes haphazardly, as a cure-all for seemingly endless conditions and health problems these days. According to a recent survey, however, marijuana really is helping many women cope with their menopause symptoms.

The arrival of menopause is associated with a number of adverse symptoms, including hot flashes and night sweats. Now, this new research shows more and more women are using marijuana, or at least want to use it, to help alleviate symptoms.

In all, 232 women (average age 56 years old) living in Northern California participated in this research. Over half report dealing with hot flashes and night sweats regularly (54%), while others deal with insomnia (27%) or genitourinary symptoms frequently (69%).

Results show over a quarter of women say they have used, or are currently using, marijuana to help battle menopause symptoms. Another 10% say they are interested in trying cannabis in the future for their menopause problems.

Perhaps just as interesting, only 19% report using a more traditional form of menopause symptom management like hormone treatment. So, it seems marijuana for menopause is more widespread than even some conventional approaches.

Despite being signed into law in July 2019, many of the improvements touted by Jake Honig’s Law, which expanded the state’s medical marijuana program, have yet to be implemented, frustrating physicians, healthcare professionals and attorneys operating in the healthcare space.

With more than 86,000 patients signed up for the medical marijuana program in New Jersey, and a ballot question asking voters to decide whether or not to legalize recreational cannabis, health care experts say many in their industry remain under informed about the medicinal value of cannabis and when or how to prescribe it.

Dr. David Nathan, founder and president of Doctors for Cannabis Regulation, said there were numerous issues the medical cannabis program still needed to address in order streamline the program including the sign-up process for patients and physicians, increasing the number of dispensaries, delivery, home cultivation and allowing nurse practitioners and physician assistants to recommend cannabis.

“My feeling is that anybody who is eligible to prescribe medication in the state of New Jersey should be eligible to recommend cannabis,” Nathan said.

Sheila Mints, a healthcare attorney with Capehart Scathard, said Jake Honig’s Law authorized nurse practitioners and physician’s assistants to register patients for the medical marijuana program but, in practice, that change has yet to take effect.

Everyone loves a little self-care, and right now, we probably all need to devote some extra time to ourselves to de-stress.

CBD (cannabidiol) and self-care seem like a match made in heaven. There are claims galore assuring you that adding CBD to your self-care routine will not only chill you out but it’ll do wonders for your anxiety. But what does the science say?

There are a plethora of CBD self-care products available to buy; from earthy deodorants, sumptuous body creams and dewy facial serums, to oils for pulse points, tension and pain relief. You can ingest CBD drops or you can soak in some hemp bath salts. All of these activities on their own are soothing and can do wonders for your anxiety when you take the time out to do them, however, there is some actual science to back up the claims that incorporating cannabidiol could lower your anxiety.

We know that CBD is currently used to treat insomnia and the chronic pain that is associated with various diseases. Studies have shown that CBD has anti-inflammatory properties which soothe physical pain and they also suggest that CBD helps people to fall and stay asleep. Both are important factors for physically relaxing your body.

But if you’re looking to address anxiety with your self-care products (which should never replace the advice or medication given by a medical practitioner), studies indicate that CBD decreases anxiety and social phobias by producing an anxiolytic effect in both animals and humans. CBD interacts with the endocannabinoid system to help restore homeostasis, meaning it helps to create a stable equilibrium within the human body and mind. In fact, CBD interacts with several receptors in the body that regulate anxiety and it’s manifesting behaviours.

Cannabis and sleep go great together. Here’s a few things you should keep in mind when using the herb to help you rest.

Marijuana can be a great tool for sleep. Just talk to any friend who smokes weed at night or who found themselves nodding off in the middle of a party because the herb they smoked was a little too relaxing.

Anecdotal evidence from people with varying degrees of insomnia shows how effective marijuana can be for sleep by helping users feel relaxed and allowing them to achieve hours of uninterrupted rest.

Despite marijuana’s powerful sleep inducing effects, it’s important to understand that the relationship between cannabis and sleep isn’t as clear cut as so many believe it is.

Here are 5 things you should keep in mind when using marijuana as a sleep aid:

Chronically ill Australians desperately trying to access medicinal cannabis could soon be given a helping hand.

Melbourne-based medicinal cannabis company Montu has created a nationwide network of doctors who support the use of controversial cannabidiol (CBD) as a treatment and can help more than half a million patients access the drug for a range of medical conditions, regardless of their location.

It will come as a welcome relief for thousands of Australians including Melbourne mother Annee Angell, whose daughter Lindsey has epilepsy.

Ms Angell said it had been an ongoing battle to find the right treatment for her 40-year-old, blind and non-verbal daughter, who would feel the debilitating effects of seizures for days after an episode.

Speaking to NCA NewsWire, Ms Angell said she discovered CBD four years ago, but she was forced to seek out a “backdoor supplier” in a bid to treat her daughter’s lifelong and “unpredictable” condition because the product was illegal.

New research out this month suggests that medical cannabis is extremely prevalent among patients looking to treat symptoms for a serious tissue disorder.

The study, which will be published in the American Journal of Medical Genetics, found that more than one-third of patients diagnosed with Ehlers-Danlos syndrome (EDS) have used marijuana to manage symptoms.

NORML, which reported on the study last week, said that the researchers found that 37 percent “reported having used cannabis therapeutically,” with cannabis use particularly prevalent “among patients who reported experiencing either moderate or severe pain.”

“Of all of the traditional and complementary therapies used by respondents, ‘marijuana was self-rated as most effective,’” NORML noted in its write-up.

What is EDS?

The National Institute of Health defines Ehlers-Danlos syndrome as “a group of disorders that affect connective tissues supporting the skin, bones, blood vessels, and many other organs and tissues,” the outlook for which can “range from mildly loose joints to life-threatening complications.” The hallmark symptoms of Ehlers-Danlos syndrome are extremely flexible joints and elastic-like skin that is susceptible to bruising.

The Malta Medicines Authority is steering standards of good practice into day-to-day excellence, regulating medicinal cannabis through an approach that upholds scientific quality, innovative research and stakeholder engagement.

As a regulatory body, the Malta Medicines Authority (MMA) provides an infrastructure that supports research and development as well as the accessibility of quality medicinal cannabis. Through guidance, technical reviews and scientific evaluations, the MMA enables controlled sourcing of cannabis-based products for the Maltese market and oversees prospective operations of local manufacturing facilities, alongside educational endeavours tailored to the evolving needs of stakeholders.

What are the main developments in Malta relevant to cannabis for medicinal and research purposes?

Medicinal cannabis gained momentum in Malta particularly over the past three years, recognising the opportunity to get policy decisions right and implement practical regulation. The 2018 amendments to the Drug Dependence (Treatment not Imprisonment) Act (Chapter 537 of the Laws of Malta) enable licensed medical practitioners to prescribe not only cannabis-based products which hold a Marketing Authorisation, but also other products which are manufactured under Good Manufacturing Practice (GMP).

The first product was made accessible to patients in Malta by May 2018, following a notification of approval issued by the Superintendence of Public Health on the recommendation of the Medicines Authority. All individual packs of the four products approved to date are serialised with tamper-evident labels upon sourcing to Malta, for traceability purposes. The product portfolios are followed up and any adverse reaction reports managed through a set procedure.

The enactment of Chapter 578 of the Laws of Malta and its subsidiary legislation, also in 2018, portended the legal provisions relevant to the production of cannabis for medicinal and research purposes. The Advanced Scientific Initiatives Directorate within the MMA developed a regulatory framework, including guidance documents which provide an overview of specific procedures such as cannabis cultivation, production, analytical considerations, licensing, security and reporting measures, enabling the implementation of a transparent system throughout all processes, including due diligence and certifications relevant to manufacturing, as well as monitoring and control.

Hill Dickinson Senior Associate Rohit Fogla explores the UK’s regulatory landscape concerning cannabis finance.

As policy on cannabis in the UK and Europe continues to evolve, Rohit Fogla, Senior Associate at Hill Dickinson LLP, outlines the current regulatory regime for medical cannabis, capital raising and investment options for enterprises and investors operating in this sector.

Medical cannabis in the UK

In November 2018, the UK government changed the law to make it possible for ‘cannabis-based products for medicinal use in humans’ (CBPMs) to be ordered and prescribed by specialist practitioners without a controlled drugs licence. At the time, it was thought this might be the gateway to further liberalisation of the restrictions on cannabis in the UK, which would foster the development of a UK medical cannabis industry.

However, due to restrictions put in place around the reforms that were introduced, only a very small number of patients with a limited range of conditions have been able to access treatment within the NHS, meaning that medical cannabis remains inaccessible for many of the patients in need.

One of the main barriers to access has been doctors’ inability or unwillingness to prescribe medicinal cannabis. This is partly due to the lack of education around cannabis available to doctors, but also due to the responsibility placed on doctors who elect to pursue this form of treatment. This has meant that those people that cannot access medical cannabis on the NHS or privately, which some estimates suggest run to the millions, are forced to purchase cannabis on the black market.

Before giving CBD oil to your ailing dog or cat, you should know something.

It’s not legal to give your pet CBD oil, a popular treatment for humans looking for help with arthritis and a host of other problems.

When the Cannabis Act was passed by the federal government and updated later to include edibles, its use for pets was not included.

“Veterinarians are not permitted to authorize medical cannabis nor are there are any products that contain cannabinoids that are approved for use in animals,” said Sarah Silcox, president of the Canadian Association of Veterinary Cannabinoid Medicine.

“So the most promising step is the government has last year proposed a new class that they have termed cannabis health products, but they would be approved by Health Canada for both human products as well as animal products,” added Silcox, who predicted that change is at least a year away.

Well-known organizations like the American Cancer Society have already had frank discussions about the benefits of CBD and cannabis during cancer treatment. 

A cancer diagnosis is a life-changing event. From the confusion of understanding the road ahead to the hectic schedule of treatment protocols and never-ending appointments, many individuals struggle through treatment and beyond.

Amy S., a native of Milwaukee, shared that her breast cancer treatment took a toll not only on her body, but relationships as well.  “Exhaustion was an understatement. I didn’t have the brain power or the patience to give to my children, or my husband.” Amy went on to explain that during particularly difficult chemotherapy sessions, while they were targeting her left breast, she had continuous nausea and insomnia. One bright spot, Amy shared, was that a friend passed her some CBD oil. 

After discussing combining the oil with her other treatment, she found relief in small doses. “It didn’t fix the fear, but it gave me a little bit of my life back, between vomiting and overthinking.” Amy credits CBD oil with helping her deal with anxiety and pain during treatment. And, she’s not alone. 

Well-known organizations like the American Cancer Society have already had frank discussions about the benefits of CBD and cannabis during cancer treatment. 

Arthritis often causes a dramatic lifestyle change that’s accompanied by depression and/or anxiety. But that doesn’t have to be the case. 

One-and-a-half million people in the United States suffer from rheumatoid arthritis (RA). In fact, The Arthritis Foundation estimates that three times as many women as men have the disease and it affects individuals of all ages, but primarily women ages 30 to 60. 

Commonly affecting the hands and feet of the body, RA is considered an autoimmune disease, where the body attacks joints, leading to inflammation and pain as well as a loss of motion. With a diagnosis comes a rapidly-changing lifestyle, often causing activities and hobbies that were once loved and now off-limits.

Through stories on the National Rheumatoid Arthritis Society website, many individuals have shared that arthritis has caused a dramatic lifestyle change that’s often accompanied by depression and anxiety. But that doesn’t have to be the case. 

Changing perceptions around cannabis with arthritis 

With patients young and old experiencing the debilitating effects of rheumatoid arthritis, individuals like Pearl Schomburg are advocating for doctors to mention the effects of cannabis in office. Pearl explained to Newshub, “Cannabis balm was the first thing I discovered and was shocked by how well it worked.”

“This study should come as good news to patients who are already using cannabis to treat pain,” explains Zach Walsh, a study co-author. “Increases in pain sensitivity with opioids can really complicate an already tough situation; given increasing uptake of cannabis-based pain medications, it’s a relief that we didn’t identify a similar pattern with cannabinoids.”

Authors of the study initially speculated that frequent cannabis users would demonstrate greater pain sensitivity, but this wasn’t the case.

Frequent opioid users run the risk of developing hyperalgesia. / Photo: Igor Vershinsky / iStock / Getty Images Plus / Photo: Igor Vershinsky / iStock / Getty Images Plus

Celebrations for medical cannabis access being added to Nebraska’s ballot in November turned out to be very short-lived. But the fight goes on.

There is no medical marijuana program in Nebraska currently and no other allowances for patients. That may have changed after the November election.

Late last month we reported Nebraskans for Medical Marijuana had announced its amendment supporting patient access to medical marijuana would appear on the November ballot. More than 182,000 petition signatures were delivered to support the initiative. However, the group expected a legal fight to keep it there and certainly got one.

Late last week, the Nebraska Supreme Court issued an opinion to remove the constitutional amendment from the ballot. Five judges ruled against the amendment’s inclusion and two supported it.

The amendment being dropped was based on a constitutional requirement that all proposed initiatives must be a “single subject”, to avoid voter confusion and attempts to have two separate and different issues being rolled into one to get something over the line. It appears the amendment was viewed to have multiple subjects, the right to access medical marijuana for medical purposes – and supply. But you can’t really have one without the other.

For Australian football player Ryan Gale, his previous years of athletic glory have been replaced by a harsh new reality.

Gales lives with chronic pain due to his injuries and required a hip replacement at just 33-years-old.

“I don’t think I ever went one week without pain somewhere,” Gale told 7NEWS.

Now Gale and other ex-athletes are hoping to benefit from a medical cannabis trial that is underway at St. Vincent’s Hospital in Melbourne and Emerald Clinics in Perth.

The trials are being conducted by Zelira Therapeutics, a medical cannabis company, and seek to demonstrate the efficacy of medical cannabis for patients who traditionally rely on opioids for chronic pain.

Focusing on novel traits of cannabis plants, a partnership among CannaPacific, Xing Technologies and Newcastle University, seeks to develop “one of the most advanced medical cannabis genomic breeding programs in the world,” notes a statement from CannaPacific.

It is hoped that engineering novel cannabis varieties with less variability and more productivity will lead to new low-cost medicinal formulations and improved delivery of products.

“There is over 100 cannabinoids in the plant, and many are still yet to be exploited,” says CannaPacific chief executive Joshua Dennis, according to the Newcastle Herald. “THC and CBD are there in the highest quantities, but there is a whole gamut of other cannabinoids in the plant in really low quantities,” Dennis says.

Minor cannabinoids, some of which have been shown to have medicinal benefits or promise, are present in strains. The trick will be identifying the new varieties with more of them.

By developing genetic markers, it will be possible to identify specific significant parts of the plant genome and “select which plants to incorporate into our breeding program in order to combine desirable traits such as specific cannabinoid profiles and yield,” Professor Christopher Grof, director of the university’s Centre for Plant Science, says in the CannaPacific release.

Medical marijuana sales from Aug. 21 through Wednesday ticked up compared to the last reporting period, according to the sales report the state revenue agency released Friday.

Daily sales during the 20-day period that ended Wednesday were $600,000 on average. The daily sales average during the 16-day reporting period that ended Aug. 20 was $592,000. The Department of Finance and Administration said the 29 dispensaries in operation during the most recent reporting period averaged $20,698 in daily sales.

About $12 million in sales from 1,766 pounds sold was reported during the 20-day period. Since the state's first legal sale of the drug in May 2019 in Garland County, dispensaries have reported $143 million in sales from 22,530 pounds sold. More than half the sales revenue occurred in the past four months.

Suite 443, where the first legal sale of the drug in Arkansas was transacted last year, was third in sales for the second-straight reporting period. It reported 119.52 pounds sold for the 20-day period that ended Wednesday. The Malvern Avenue dispensary in unincorporated Garland County was second in sales during the 21-day period that ended Aug. 4 and fourth during the 19-day period that ended July 14.

Green Springs Medical, the only dispensary in Hot Springs' city limits, ranked 11th with 71.4 pounds sold. It was the daily sales average leader for more than a year, but as more dispensaries have come online its market share has shrunk.

The aging process for humans can really be a sad thing.

As time goes by the human body starts to break down and condition(s) develop.

Unfortunately, it’s a reality that cannot be overcome.

Getting older can be a tough thing to navigate for many people.

The aches and pains are a constant reminder that Father Time is undefeated.

Curaleaf, the state’s largest medical marijuana company, has announced it will open its second New Jersey dispensary in Bordentown Township early next year.

The Massachusetts-based company announced it will open its first satellite dispensary on Route 130 North. It currently operates a dispensary and cultivation site as Curaleaf NJ in Bellmawr.

The company said it will begin construction on its 9,000-square-foot dispensary in the fall. It has 92 dispensaries in 23 states.

The dispensary is one of several expected to open in the coming months, including MPX NJ in Atlantic City, TerrAscend in Phillipsburg and a second location of Harmony in Hoboken.

That will bring the total number of dispensaries in the state to 15. But more than 85,000 patients have enrolled in the program, and they often face lines, product shortages and long drives to get to dispensaries.